Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small interfering RNA-based therapeutics - Alnylam

Drug Profile

Research programme: small interfering RNA-based therapeutics - Alnylam

Alternative Names: 5 x 15™ programme - Alnylam; ALAS-1 siRNA; ALN ANG; ALN F12; ALN-AC3; ALN-APC; ALN-HDV; ALN-HPN; ALN-PDL; ALN-TMP; DLin-MC3-DMA LNP; ESC-GalNAc-Conjugate-HBV

Latest Information Update: 12 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Sanofi Genzyme; Technical University Munich; University of Heidelberg
  • Class Small interfering RNA
  • Mechanism of Action ANGPTL3 protein inhibitors; Antithrombin III inhibitors; Factor XII inhibitors; Glycolate oxidase expression inhibitors; Hepcidin inhibitors; Prealbumin inhibitors; Programmed cell death-1 ligand-1 inhibitors; RNA interference; TMPRSS6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A; Primary hyperoxaluria; Haemophilia B
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis B; Hereditary angioedema
  • Suspended Anaemia
  • No development reported Adenovirus infections; Amyloidosis; Haemoglobinopathies; Haemophilia; Hepatitis; Hepatitis D; Hyperlipoproteinaemia type V; Hypertriglyceridaemia; Inborn genetic disorders; Liver disorders; Metabolic disorders; Primary hyperoxaluria

Most Recent Events

  • 08 Apr 2019 Alnylam amends equity agreement with Sanofi
  • 28 Mar 2019 No recent reports of development identified for research development in Hepatitis in USA
  • 28 Mar 2019 No recent reports of development identified for research development in Inborn genetic disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top